Grupo Casa Saba, S.A. de C.V. Announces Fourth Quarter 2006 Results
February 28 2007 - 9:25AM
PR Newswire (US)
Operating Income and Net Income Increased 8.2% and 29.5%,
Respectively MEXICO CITY, Feb. 28 /PRNewswire-FirstCall/ -- Grupo
Casa Saba ("Saba," "GCS," "the company" o "the Group"), one of the
leading Mexican distributors of pharmaceutical products, beauty
aids, personal care and consumer goods, general merchandise,
publications and other products announces its consolidated
financial and operating results for the fourth quarter of 2006. All
figures are expressed in millions of pesos as of December 31, 2006.
Variations presented compare the period with the same period in
2005, unless otherwise stated. Figures may vary due to rounding
practices. "bp" stands for basis points. NET SALES During the
fourth quarter of 2006, Grupo Casa Saba sales decreased 0.83% when
compared to the same 2005 quarter. The decline mainly reflects a
high comparison base for Private Pharma sales and lower sales to
the government, as well as health and beauty products. It's worth
mentioning that during 2005's fourth quarter, and particularly
during month of December that year, special season sales took place
and triggered a double-digit growth in the period. In December
2006, the Private Pharma market did not offer the same conditions
to reach the sales volumes registered in 2005, affecting the growth
rate of our main division, Private Pharma. Sales of Publications
and Food Products rose 12.48% and 8.33%, respectively. The
increases reflect a good acceptance of our catalogs of products in
the different markets where we operate. SALES BY DIVISION PRIVATE
PHARMA During 2006's fourth quarter sales in our Private Pharma
divisions rose 0.90%. This modest growth reflects a high comparison
base, particularly in December. Special end of season sales in the
last month of 2006 could not match those of 2005, as the market for
private pharmaceuticals did not offer the conditions to reach
December 2005 sales. Even when December was a difficult month in
terms of comparison for this division, the positive performance of
the national private pharmaceuticals market in terms of values,
allowed quarter sales to reach $5,616.53 million, while its
percentage to total sales increased to 85.19% in 4Q06 from 83.73%
in 4Q05. GOVERNMENT PHARMA Sales of our Government Pharma division,
which include sales to government institutions, whether federal or
state, decreased 26.59%, as sales to Petroleos Mexicanos (PEMEX)
declined. Lower sales to PEMEX stem from an internal modification
applied by the institution to their subrogation scheme of
pharmaceutical products. With sales decreasing, the percentage to
total sales of this division also declined from 4.63% in 4Q05 to
3.43% in 4Q06. HEALTH, BEAUTY, CONSUMER GOODS, GENERAL MERCHANDISE
AND OTHER Mainly as a result of lower sales of health and beauty
products, sales from this division, which include products other
than pharmaceuticals and publications, declined 7.79% during 2006's
fourth quarter. The reduction in health and beauty products sales
stems mainly from the decision made by some of our clients not to
buy these type of products from GCS. Conversely, food products
sales had a good performance, increasing 8.33% with respect to
4Q05. As a percentage to total sales, the sales reduction in this
division affected its contribution to total sales, declining from
8.92% in 4Q05 to 8.28% in 4Q06. PUBLICATIONS Citem's which is GCS'
subsidiary that distributes publications nation wide (mainly
magazines), increased sales by 12.48% from 4Q05. The increase stems
from a better distribution of products by type of client in the
different niches where it operates, along with a greater acceptance
and demand for year-end editions. As a result, the division's
percentage to total sales grew from 2.73% in 4Q05 to 3.10% in 4Q06.
GROSS INCOME Grupo Casa Saba's gross income during the fourth
quarter of 2006 decreased 3.97% from the same 2005 period. Lower
sales and greater discounts offered contributed to this decrease.
The increase in discounts stems from the strong competition that
prevails in all channels of the private pharmaceutical market.
OPERATING EXPENSES The operating expenses of the Group as a
percentage to total sales decreased by 87 b.p. to 5.43%. Operating
expenses performance during the fourth quarter of 2006 was
influenced by storage and route efficiency programs, as well as by
corporate and administrative expense savings schemes. Total
operating expenses for the Group declined 14.46% from 4Q05, or
$60.59 million. OPERATING INCOME Given that the reduction in
expenses was proportionately above the lower gross income, GCS's
operating income increased 8.18% from 4Q05. As a percentage of
total sales, operating income of the Group represented 5.45% in
4Q05 and closed at 5.94% in 4Q06. OPERATING INCOME PLUS
DEPRECIATION AND AMORTIZATION Depreciation and amortization in 4Q06
decreased 56.79% from 4Q05, as the Group's computer equipment
stopped depreciating a few months ago and a goodwill registered in
the fourth quarter of 2005 was not registered in 4Q06. Operating
income plus depreciation and amortization in 4Q06 increased 0.35%
from the same previous quarter, amounting to $413.12 million. CASH
AND CASH EQUIVALENTS Cash and cash equivalents in 4Q06 totaled
$616.38 million pesos, representing a 17.09% decreased from 4Q05.
The decline in the cash position owes to higher investment in
working capital of the Group. COMPREHENSIVE COST OF FINANCING The
comprehensive cost of financing (CCF) in the fourth quarter
generated an income of $6.45 million, 109.18% above the income in
4Q05. This growth mainly stems from a gain during the fourth
quarter in our monetary and exchange rate positions, compared to a
losses registered in 4Q05. OTHER EXPENSES/INCOME Other
expenses/income in 4Q06 totaled $125.54 million, as a result of
transportation equipment sales, third-party services and others.
TAX PROVISIONS Tax provisions for 4Q06 increased 85.60% from 4Q05.
The relationship between tax provisions and income before taxes
represented 18.39% in 4Q05 and closed at 24.40% in 4Q06. NET INCOME
GCS' net income in 4Q06 increased 29.45%, or $89.93 million, to
$395.34 million. Net income as a percentage of total sales
increased from 4.59% in 4Q05 to 6.00% 4Q06. WORKING CAPITAL During
the fourth quarter of 2006, account receivables measured in terms
of days increased from 2005 by 0.3 days to 55.3 days. Inventory
days also grew by 3.50 days to 60.8 days. Account payables,
conversely, decreased by 0.90 days to 52.2 days. DATASOURCE: Grupo
Casa Saba, S.A. de C.V. CONTACT: Jorge Sanchez, Investor Relations,
+011-52-55-5284-6672, or , or Jesus Martinez Rojas, IR
Communications, +011-52-55-5644-1247, or , or Alejandro Sadurni,
CFO, , all of Grupo Casa Saba Web site: http://www.casasaba.com/
Copyright